Sulphur burps and Rybelsus are connected through the medication's effect on digestive motility. Rybelsus (semaglutide), an oral GLP-1 receptor agonist for type 2 diabetes, slows gastric emptying as part of its therapeutic action. This delayed digestion can create conditions where hydrogen sulphide gas forms, producing the characteristic rotten egg odour of sulphur burps. Whilst not listed as a specific adverse effect in the Summary of Product Characteristics, belching and gastrointestinal disturbances are common with Rybelsus, particularly during initial treatment. Understanding this connection helps patients manage symptoms effectively whilst benefiting from improved glycaemic control.
Quick Answer: Sulphur burps may occur with Rybelsus because the medication slows gastric emptying, allowing increased bacterial fermentation and hydrogen sulphide production in the digestive tract.
Sulphur burps, medically termed eructation with a hydrogen sulphide odour, are characterised by belching that produces a distinctive smell reminiscent of rotten eggs. This unpleasant odour results from hydrogen sulphide gas, which forms when sulphur-containing proteins are broken down in the digestive system. Whilst occasional sulphur burps are generally harmless, frequent episodes can indicate underlying digestive disturbances.
The production of hydrogen sulphide typically occurs when food remains in the digestive tract longer than usual, allowing bacterial fermentation to take place primarily in the gut (mainly small intestine and colon). Common dietary triggers include:
High-protein foods (particularly red meat, eggs, and dairy products)
Cruciferous vegetables such as broccoli, cabbage, and Brussels sprouts
Some foods containing preservatives
Carbonated beverages that introduce excess gas
Beyond dietary factors, sulphur burps may arise from conditions affecting gastric emptying or digestive motility. Gastroparesis (delayed stomach emptying), small intestinal bacterial overgrowth (SIBO), gastro-oesophageal reflux disease (GORD), and certain infections like giardiasis or Helicobacter pylori can all contribute to this symptom. Medications that slow gastrointestinal transit may also increase the likelihood of sulphur burp occurrence.
In most cases, sulphur burps resolve spontaneously once the triggering food has been digested or the underlying cause addressed. However, when they occur persistently or alongside other symptoms such as abdominal pain, diarrhoea, or vomiting, medical evaluation is warranted to exclude more significant gastrointestinal pathology. Understanding the mechanism behind sulphur burps helps contextualise why certain medications, including Rybelsus, may contribute to this side effect.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereRybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. As the first oral formulation in this drug class, it offers an alternative to injectable GLP-1 agonists whilst maintaining similar efficacy in glycaemic control. Understanding its mechanism of action is essential to appreciating why gastrointestinal side effects, including sulphur burps, may occur.
Semaglutide exerts its therapeutic effects through several mechanisms:
Enhancing glucose-dependent insulin secretion from pancreatic beta cells
Suppressing inappropriate glucagon release
Slowing gastric emptying, particularly during early treatment
Reducing appetite through central nervous system pathways
The slowing of gastric emptying, whilst beneficial for glycaemic control and weight management, creates conditions that may contribute to belching and gas formation. When food remains in the digestive tract for extended periods, protein breakdown and bacterial fermentation increase, potentially leading to hydrogen sulphide production. This delayed gastric emptying effect is typically most pronounced during the initial weeks of treatment and may attenuate over time.
Additionally, the appetite-suppressing effects may alter eating patterns, potentially leading to irregular meal timing or consumption of foods that are more difficult to digest. Some patients report that high-fat or high-protein meals seem particularly problematic when taking Rybelsus, likely due to the compounded effect of naturally slower digestion of these macronutrients combined with medication-induced gastric delay.
It is important to note that there is no official link in the Summary of Product Characteristics (SmPC) suggesting Rybelsus directly produces sulphur compounds; rather, the medication's effect on gastrointestinal motility may create an environment where belching and associated odours are more likely to develop in susceptible individuals.
Rybelsus must be taken correctly: on an empty stomach with no more than 120 ml of water, waiting at least 30 minutes before consuming food, drink, or other oral medicines. The tablet should be swallowed whole and not crushed or split.
Gastrointestinal adverse effects represent the most frequently reported side effects associated with Rybelsus, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation. According to the MHRA/EMC Summary of Product Characteristics (SmPC), these effects are well-documented.
The most common gastrointestinal side effects include:
Nausea – very common (may affect more than 1 in 10 people), most pronounced during the first 4-5 weeks
Diarrhoea – common (may affect up to 1 in 10 people)
Vomiting – common (may affect up to 1 in 10 people)
Abdominal pain – common (may affect up to 1 in 10 people)
Constipation – common (may affect up to 1 in 10 people)
Dyspepsia and flatulence – common (may affect up to 1 in 10 people)
Whilst belching may occur, 'sulphur burps' are not specifically enumerated as a distinct adverse effect in the SmPC. They fall within the broader category of gastrointestinal disturbances, though precise incidence data remain limited.
It is also important to note that GLP-1 receptor agonists including Rybelsus are associated with an increased risk of gallbladder disorders, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation). Patients should be alert to symptoms such as right upper quadrant pain, fever, or jaundice, which warrant prompt medical assessment.
The severity of gastrointestinal side effects typically diminishes over time as physiological adaptation occurs. Most patients experience peak symptoms during the first month of therapy, with gradual improvement thereafter. The recommended titration schedule—starting at 3 mg daily for one month before increasing to 7 mg, and potentially to 14 mg after a further month—is specifically designed to minimise gastrointestinal intolerance.
According to NICE guidance on type 2 diabetes management (NG28), healthcare professionals should counsel patients about expected side effects before initiating GLP-1 receptor agonist therapy, emphasising that most gastrointestinal symptoms are transient and manageable with appropriate strategies.
Effective management of sulphur burps whilst continuing Rybelsus therapy involves a combination of dietary modifications, lifestyle adjustments, and practical strategies to minimise symptom burden. Most patients can achieve satisfactory control without discontinuing treatment, allowing them to benefit from the medication's glycaemic and potential weight management effects.
Dietary modifications form the cornerstone of management:
Reduce sulphur-rich foods: Temporarily limit red meat, eggs, cruciferous vegetables, garlic, and onions to identify triggers
Eat smaller, more frequent meals: This approach reduces the volume of food requiring digestion at any one time, potentially decreasing fermentation
Avoid high-fat meals: Fatty foods further delay gastric emptying, compounding the effect of Rybelsus
Stay well-hydrated: Adequate fluid intake supports digestive processes and may help reduce gas formation
Limit carbonated beverages: These introduce additional gas into the digestive system
Practical lifestyle strategies include:
Taking Rybelsus correctly—on an empty stomach with no more than 120 ml of water, waiting at least 30 minutes before eating, drinking, or taking other oral medicines—ensures optimal absorption and may reduce gastrointestinal effects
Swallowing the tablet whole (do not split or crush)
Eating slowly and chewing thoroughly to aid digestion
Avoiding lying down immediately after meals, which can exacerbate reflux and delayed emptying
Gentle physical activity after eating, such as a short walk, may promote gastric emptying
Over-the-counter remedies that some patients find helpful include simethicone-containing products (which help disperse gas bubbles) and probiotics, though evidence for their efficacy specifically with GLP-1 agonists is limited. Before adding any supplements or over-the-counter medications, patients should consult their GP or pharmacist to ensure compatibility with their diabetes management regimen.
Keeping a symptom diary can help identify specific triggers and patterns, enabling more targeted interventions. If symptoms persist despite these measures, discussing dose adjustment or slower titration with your healthcare provider is appropriate.
Whilst gastrointestinal side effects including sulphur burps are common with Rybelsus and often manageable, certain symptoms warrant prompt medical evaluation. Distinguishing between expected, self-limiting effects and those requiring clinical assessment is essential for patient safety and optimal diabetes management.
Contact your GP or diabetes specialist nurse if you experience:
Persistent or severe nausea and vomiting that prevents adequate food or fluid intake, as this increases the risk of dehydration and hypoglycaemia
Abdominal pain, particularly if constant or worsening
Signs of dehydration including reduced urination, dizziness, dry mouth, or confusion
Unexplained weight loss beyond what is expected from the medication's appetite-suppressing effects
Blood in vomit or stools, which requires urgent assessment
Symptoms of hypoglycaemia (shakiness, sweating, confusion) if taking Rybelsus alongside sulfonylureas or insulin
Right upper quadrant pain, fever, or jaundice, which could indicate gallbladder disease—a known risk with GLP-1 receptor agonists
New or worsening visual symptoms if you have pre-existing diabetic retinopathy
Seek immediate medical attention (call 999 or attend A&E) if you develop:
Severe, persistent abdominal pain radiating to the back (potential pancreatitis)—stop taking Rybelsus immediately if pancreatitis is suspected
Signs of severe allergic reaction (difficulty breathing, facial swelling, severe rash)
Symptoms suggesting diabetic ketoacidosis (excessive thirst, frequent urination, confusion, fruity breath odour)—this is rare but may occur, particularly if insulin has been rapidly reduced or discontinued
If sulphur burps and other gastrointestinal symptoms persist beyond the first 4-6 weeks of therapy despite dietary modifications, or if they significantly impair quality of life, schedule a routine appointment to discuss management options. Your GP may consider dose adjustment, additional symptomatic treatment, or alternative diabetes medications if side effects prove intolerable.
Regular monitoring as recommended by NICE guidelines—including HbA1c measurements, renal function tests, and assessment of treatment tolerability—ensures that Rybelsus therapy remains both safe and effective. Open communication with your healthcare team about side effects facilitates optimal diabetes management and helps prevent complications.
Suspected side effects can also be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).
Sulphur burps and other gastrointestinal side effects typically peak during the first 4–6 weeks of Rybelsus treatment and gradually improve as your body adapts to the medication. If symptoms persist beyond this period despite dietary modifications, consult your GP to discuss management options.
Whilst you cannot entirely prevent sulphur burps, you can reduce their frequency by limiting sulphur-rich foods (red meat, eggs, cruciferous vegetables), eating smaller meals, avoiding high-fat foods, and ensuring you take Rybelsus correctly on an empty stomach with no more than 120 ml of water.
Do not stop Rybelsus without consulting your healthcare provider. Sulphur burps are generally manageable with dietary adjustments and typically improve over time. However, if symptoms are severe, persistent, or accompanied by concerning signs such as severe abdominal pain or vomiting, contact your GP to discuss your treatment options.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
